Condition
Mucopolysaccharidosis Type VI
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03173521Phase 1CompletedPrimary
Gene Therapy in Patients With Mucopolysaccharidosis Disease
NCT01870375Completed
Longitudinal Studies of Brain Structure and Function in MPS Disorders
NCT02437253Phase 1Completed
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Showing all 3 trials